Doctors Revision

Palliative Care

Nausea and Vomiting in Palliative Care

Management of nausea and vomiting in patients with life-limiting illness, considering various potential causes.

Also known as: N/V Management

Open in the interactive guide
On this page

Referral and warning signs

When to refer

Persistent N/V unresponsive to first-line antiemetics. Suspected bowel obstruction requiring specialist assessment/intervention. Need for complex antiemetic combinations or parenteral routes.

Red flags

  • Signs of severe dehydration (tachycardia, hypotension, poor turgor).
  • Persistent vomiting, inability to tolerate oral intake.
  • Vomiting blood (haematemesis) or 'coffee grounds'.
  • Signs of bowel obstruction (abdominal distension, pain, absent bowel sounds).
  • Neurological signs suggesting raised ICP (headache, papilloedema, altered consciousness).

Signs and symptoms

  • Subjective feeling of nausea (urge to vomit).
  • Vomiting (emesis).
  • Retching.

Risk factors

  • Gastrointestinal issues (constipation, gastric stasis, obstruction).
  • Metabolic disturbances (uraemia, hypercalcaemia, liver failure).
  • Medications (opioids, chemotherapy, antibiotics).
  • Raised intracranial pressure (brain tumours).
  • Infections.
  • Anxiety.

Diagnosis

Clinical assessment

Detailed history: Onset, frequency, timing (relation to meals/meds), triggers, volume/nature of vomitus, associated symptoms (pain, constipation, headache, dizziness). Physical exam: Abdominal assessment (distension, bowel sounds), hydration status, neurological exam (if ICP suspected). Identify likely mechanism/cause.

Investigations

  • Directed by clinical suspicion:
  • - Blood tests: Electrolytes, Urea, Creatinine, Calcium, LFTs.
  • - Imaging: Abdominal X-ray/Ultrasound (if obstruction suspected), CT/MRI head (if raised ICP suspected).

Diagnostic criteria

Clinical assessment identifying likely cause to guide targeted antiemetic choice.

Management

Non-pharmacological management

  • Treat the underlying cause if possible (e.g., manage constipation, correct electrolytes).
  • Dietary modification: Small, frequent meals; avoid fatty, spicy, or strong-smelling foods.
  • Maintain hydration (oral sips, IV/SC fluids if needed and appropriate).
  • Ensure good oral hygiene.
  • Acupressure/Acupuncture (limited evidence).

Pharmacological treatment

  • Select antiemetic based on likely cause:
  • - Gastric Stasis / Delayed Transit: Metoclopramide 10-20mg PO/SC/IV Q8H (30 mins before meals). Child doses in UCG.
  • - Metabolic / Chemical / Drug-Induced (Chemoreceptor Trigger Zone - CTZ): Haloperidol 1.25-2.5mg PO/SC nocte. (Consider Ondansetron for chemotherapy-induced N/V - specialist guidance).
  • - Raised Intracranial Pressure: Dexamethasone 8-16mg OD.
  • - Visceral Stretch / Compression / Bowel Obstruction: Promethazine 25mg PO Q8H OR Hyoscine Butylbromide 20-40mg PO/SC Q8H.
  • - Vestibular causes (less common in palliative): Consider antihistamines like Cinnarizine or Cyclizine.
  • - Anxiety-related: Lorazepam or Diazepam may help.
  • Combine antiemetics with different mechanisms if needed.

Monitoring

Assess effectiveness of antiemetic therapy. Monitor hydration status and electrolytes. Monitor for side effects of antiemetics (e.g., extrapyramidal effects with metoclopramide/haloperidol, sedation).

Complications

  • Dehydration.
  • Electrolyte imbalance (hypokalaemia, metabolic alkalosis).
  • Aspiration pneumonia.
  • Malnutrition.
  • Poor quality of life, distress.

Prevention

  • Prophylactic antiemetics when using known emetogenic drugs (opioids, chemo).
  • Manage constipation proactively.
  • Address underlying causes promptly.

Patient education

  • Explanation of likely cause.
  • How to take antiemetic medication correctly (timing).
  • Dietary and hydration advice.
  • Importance of reporting persistent symptoms.
  • Side effects to watch for.

Uganda-specific notes

Common antiemetics like Metoclopramide, Haloperidol, Promethazine are usually available. Identifying the likely cause helps choose the most effective agent. Consider empirical treatment if investigations limited.

References

  • Uganda Clinical Guidelines (UCG) 2023

    Chapter 13, Section 13.2.2

Scroll to Top